Biomind Labs Inc (BMND) - Net Assets

Latest as of September 2025: CA$-1.56 Million CAD ≈ $-1.13 Million USD

Based on the latest financial reports, Biomind Labs Inc (BMND) has net assets worth CA$-1.56 Million CAD (≈ $-1.13 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$57.72K ≈ $41.75K USD) and total liabilities (CA$1.62 Million ≈ $1.17 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read debt load of Biomind Labs Inc for a breakdown of total debt and financial obligations.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CA$-1.56 Million
% of Total Assets	-2702.98%
Annual Growth Rate	N/A
5-Year Change	N/A
10-Year Change	N/A
Growth Volatility	N/A

Biomind Labs Inc - Net Assets Trend (2021–2024)

This chart illustrates how Biomind Labs Inc's net assets have evolved over time, based on quarterly financial data. Also explore BMND current and non-current assets for the complete picture of this company's asset base.

Annual Net Assets for Biomind Labs Inc (2021–2024)

The table below shows the annual net assets of Biomind Labs Inc from 2021 to 2024. For live valuation and market cap data, see BMND market cap overview.

Year	Net Assets	Change
2024-12-31	CA$-1.30 Million ≈ $-940.54K	+9.21%
2023-12-31	CA$-1.43 Million ≈ $-1.04 Million	-478.27%
2022-12-31	CA$-247.66K ≈ $-179.15K	-111.29%
2021-12-31	CA$2.19 Million ≈ $1.59 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Biomind Labs Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 443843300.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Other Components	CA$13.58 Million	%
Total Equity	CA$-1.30 Million	100.00%

Biomind Labs Inc Competitors by Market Cap

The table below lists competitors of Biomind Labs Inc ranked by their market capitalization.

Company	Market Cap
Biotricity Inc NASDAQ:BTCY	$6.98 Million
Kanger International Bhd KLSE:0170	$6.98 Million
Perrot Duval Holding SA SW:PEDU	$6.99 Million
Augros Cosmetic Packaging SA PA:AUGR	$6.99 Million
Aeris Environmental Ltd AU:AEI	$6.98 Million
Total Telcom Inc V:TTZ	$6.98 Million
Torr Metals Inc V:TMET	$6.97 Million
Curative Biotechnology Inc NYSE MKT:CUBT	$6.97 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Biomind Labs Inc's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from -1,432,120 to -1,300,192, a change of 131,928.
Net loss of 260,479 reduced equity.
Other factors increased equity by 392,407.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CA$-260.48K	-20.03%
Other Changes	CA$392.41K	+30.18%
Total Change	CA$-	%

Book Value vs Market Value Analysis

This analysis compares Biomind Labs Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2021-12-31	CA$0.03	CA$0.19	x
2022-12-31	CA$0.00	CA$0.19	x
2023-12-31	CA$-0.02	CA$0.19	x
2024-12-31	CA$-0.02	CA$0.19	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Biomind Labs Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 0.00%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.00%
• Asset Turnover: 0.00x
• Equity Multiplier: 0.00x
Recent ROE (0.00%) is above the historical average (-49.39%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2021	-197.55%	0.00%	0.00x	1.15x	CA$-4.55 Million
2022	0.00%	0.00%	0.00x	0.00x	CA$-2.96 Million
2023	0.00%	0.00%	0.00x	0.00x	CA$-1.05 Million
2024	0.00%	0.00%	0.00x	0.00x	CA$-130.46K

Industry Comparison

This section compares Biomind Labs Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $27,043,949
Average return on equity (ROE) among peers: -421.37%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Biomind Labs Inc (BMND)	CA$-1.56 Million	-197.55%	N/A	$6.98 Million
Appili Therapeutics Inc (APLI)	$-13.40 Million	0.00%	0.00x	$1.86 Million
Aptose Biosciences Inc (APS)	$7.33 Million	-189.11%	0.18x	$4.36 Million
Arch Biopartners Inc (ARCH)	$1.06 Million	-79.15%	0.19x	$20.88 Million
Cybin Inc (CYBN)	$237.20 Million	-47.70%	0.09x	$301.37 Million
Eupraxia Pharmaceuticals Inc (EPRX)	$1.18 Million	-3177.89%	21.71x	$393.86 Million
Devonian Health Group Inc (GSD)	$14.25 Million	-32.28%	0.35x	$20.01 Million
Helix BioPharma Corp. (HBP)	$-1.39 Million	0.00%	0.00x	$116.58 Million
Hemostemix Inc (HEM)	$-6.77 Million	0.00%	0.00x	$8.18 Million
Universal Ibogaine Inc (IBO)	$3.94 Million	-266.20%	0.60x	$1.13 Million

About Biomind Labs Inc

NEO:BMND Canada Biotechnology

Market Cap

$10.38 Million

CA$14.35 Million CAD

Market Cap Rank

#27686 Global

#1219 in Canada

Share Price

CA$0.19

Change (1 day)

+68.18%

52-Week Range

CA$0.01 - CA$0.35

All Time High

CA$1.90